Molecular Therapeutics Theme 3 Accomplishments

Theme 3: Validate clinical effectiveness of new agents and new protocols in interventional treatment trials

Scientific Accomplishments

In preclinical triple-negative breast cancer (TNBC) models, Drs. Boerner, Polin and Heilbrun, working with Dr. LoRusso, found that poly (ADP-ribose) polymerase (PARP) inhibitors such as veliparib (ABT-888) enhanced the activity of the topoisomerase 1 inhibitor irinotecan (CPT-11). Based on these results, a Phase I clinical trial was performed to examine the tolerability of combined veliparib/ironotecan in advanced solid tumor patients. Following the dose-escalation phase, an expansion cohort was opened to perform further biomarker and genomic correlative studies in two specific TNBC populations with the combined veliparib/irinotecan.

  • Lead researchers - Drs. Boerner, Polin and Heilbrun.
  • Collaborative researcher - Dr. Li

Dr. Gadgeelwas a Principal Investigators on a phase I/II study evaluating CH5424802 (alectinib), a second generation ALK (anaplastic lymphoma kinase) inhibitor in patients with ALK positive NSCLC (non-small cell lung cancer) whose disease had progressed following treatment with the first generation ALK inhibitor crizotinib. Based on the results of the phase II trial, the drug has received ‘breakthrough designation’ by the US FDA.

  • Lead researchers - Dr. Gadgeel

The Latest From Karmanos Cancer Institute

News

Karmanos welcomes new VP of the Karmanos Cancer Network

The Barbara Ann Karmanos Cancer Institute has appointed Doris Ranski-Zazula, RN, MSA, as the vice president of the Karmanos Cancer Network , part ...

Read More

12 thoughtful holiday gift ideas for loved ones going through cancer treatment

If you have a loved one receiving cancer treatment during the holidays, they might spend long hours in clinics daily. Here are some great gift ide...

Read More

Stage IV lung cancer survivor, disparities cancer researcher, family physician appointed as Karmanos' new associate center director

The Barbara Ann Karmanos Cancer Institute welcomes Morhaf Al Achkar, M.D., Ph.D., MSCR, FAAFP, as the associate center director for Education. Dr....

Read More
News

IN THE NEWS: Karmanos’ new CEO on new cancer treatments, research and growth

Listen Now

IN THE NEWS: Don’t be afraid to ‘get that mammogram’

Listen Now

IN THE NEWS: 11-year breast cancer survivor shares her story, ‘I’m a medical miracle’

Listen Now